Physician profile
Stephen A Mechtler
NPI 1558321372
$9,183.33
in general payments reported to CMS, 2019-2025
43 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $1,167 · 2021: $1,417 · 2022: $1,690 · 2023: $1,339 · 2024: $985 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,429.30 |
| Education | $142.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $1,113.86 | 2021-2025 | Annovera, Nextstellis |
| Amgen INC. | $1,005.00 | 2019-2024 | Prolia, Evenity |
| Astellas Pharma US INC | $796.34 | 2022-2025 | Veozah, Myrbetriq |
| Avion Pharmaceuticals | $753.05 | 2019-2021 | |
| Abbvie INC. | $674.03 | 2019-2024 | |
| Therapeuticsmd, INC. | $653.51 | 2019-2022 | |
| Pfizer INC. | $577.44 | 2019-2024 | |
| Agile Therapeutics, INC. | $507.00 | 2021-2023 | Twirla |
| Exact Sciences Corporation | $357.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Exeltis, USA INC. | $316.44 | 2019-2025 | Slynd |
| Myovant Sciences INC. | $293.29 | 2021-2022 | |
| Allergan, INC. | $285.20 | 2019-2020 | |
| Millicent US INC | $178.54 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Lupin INC. | $177.04 | 2019-2020 | |
| Scynexis, INC. | $170.47 | 2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $146.63 | 2021-2025 | Nexplanon, Nuvaring, Jada System |
| Duchesnay USA Incorporated | $143.47 | 2019 | |
| Sumitomo Pharma America, INC. | $112.13 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $100.48 | 2019-2024 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $96.66 | 2020-2022 | |
| Hologic Sales and Service, LLC | $92.33 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Biocryst US Sales Co., LLC | $68.97 | 2024-2025 | Orladeyo |
| Vertical Pharmaceuticals, LLC | $54.96 | 2019 | |
| Octapharma USA, INC. | $46.48 | 2023-2025 | Octagam Immune Globulin (Human) |
| Mycovia Pharmaceuticals, INC. | $46.43 | 2023 | Vivjoa |
| Bayer Healthcare Pharmaceuticals INC. | $39.26 | 2019 | |
| Roche Diagnostics Corporation | $37.62 | 2021 | |
| Mckesson Patient Care Solutions INC. | $30.42 | 2019 | |
| Gilead Sciences, INC. | $28.54 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $27.80 | 2025 | Saphnelo |
| Ucb, INC. | $27.32 | 2025 | Bimzelx |
| Daiichi Sankyo INC. | $25.43 | 2021-2023 | Injectafer |
| Abbott Laboratories | $22.74 | 2025 | Freestyle Libre 3 |
| Insulet Corporation | $22.72 | 2025 | Omnipod |
| Radius Health, INC. | $22.08 | 2022 | |
| Becton, Dickinson and Company | $19.16 | 2023 | Bd Surepath Collection Vial |
| Kowa Pharmaceuticals America, INC. | $18.01 | 2023 | Livalo, Seglentis |
| Ibsa Pharma INC. | $17.22 | 2025 | Licart, Flector, Tirosint |
| Coopersurgical, INC. | $17.07 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.60 | 2019 | |
| Celltrion USA INC. | $15.55 | 2023 | Yuflyma |
| Biogen, INC. | $14.78 | 2023 | |
| Lilly USA, LLC | $13.47 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mechtler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.